1. Home
  2. APLM vs ABVE Comparison

APLM vs ABVE Comparison

Compare APLM & ABVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • ABVE
  • Stock Information
  • Founded
  • APLM 2016
  • ABVE 2019
  • Country
  • APLM United States
  • ABVE Canada
  • Employees
  • APLM N/A
  • ABVE N/A
  • Industry
  • APLM Blank Checks
  • ABVE Packaged Foods
  • Sector
  • APLM Finance
  • ABVE Consumer Staples
  • Exchange
  • APLM Nasdaq
  • ABVE Nasdaq
  • Market Cap
  • APLM 15.6M
  • ABVE 18.0M
  • IPO Year
  • APLM N/A
  • ABVE N/A
  • Fundamental
  • Price
  • APLM $7.89
  • ABVE $0.51
  • Analyst Decision
  • APLM Strong Buy
  • ABVE
  • Analyst Count
  • APLM 2
  • ABVE 0
  • Target Price
  • APLM $425.00
  • ABVE N/A
  • AVG Volume (30 Days)
  • APLM 106.0K
  • ABVE 828.4K
  • Earning Date
  • APLM 08-14-2024
  • ABVE 02-15-2025
  • Dividend Yield
  • APLM N/A
  • ABVE N/A
  • EPS Growth
  • APLM N/A
  • ABVE N/A
  • EPS
  • APLM N/A
  • ABVE N/A
  • Revenue
  • APLM $2,101,000.00
  • ABVE $275,376,450.00
  • Revenue This Year
  • APLM N/A
  • ABVE N/A
  • Revenue Next Year
  • APLM N/A
  • ABVE N/A
  • P/E Ratio
  • APLM N/A
  • ABVE N/A
  • Revenue Growth
  • APLM 70.54
  • ABVE N/A
  • 52 Week Low
  • APLM $6.50
  • ABVE $0.34
  • 52 Week High
  • APLM $105.00
  • ABVE $4.07
  • Technical
  • Relative Strength Index (RSI)
  • APLM 42.42
  • ABVE N/A
  • Support Level
  • APLM $7.70
  • ABVE N/A
  • Resistance Level
  • APLM $8.88
  • ABVE N/A
  • Average True Range (ATR)
  • APLM 1.34
  • ABVE 0.00
  • MACD
  • APLM -0.04
  • ABVE 0.00
  • Stochastic Oscillator
  • APLM 24.77
  • ABVE 0.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About ABVE Above Food Ingredients Inc. Common Stock

Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.

Share on Social Networks: